RESPITE Study Results
Recent advances in pulmonary hypertension have led to evolution of strategic approaches to treatment. In patients on therapy, who are exhibiting a decline in function, escalation of combination therapy has been a standard method. The recent RESPITE trial, however, explored the switch of patients, failing on PDE5 inhibitor therapy, to the soluble guanylate cyclase inhibitor, riociguat. Dr. James White describes the rationale, design and principal efficacy and safety results of this important study.